---
title: "InnoCare Pharma erhält IND-Zulassung für klinische Studie mit VAV1-Degrader ICP-538 in China"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275256031.md"
datetime: "2026-02-09T02:43:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275256031.md)
  - [en](https://longbridge.com/en/news/275256031.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275256031.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275256031.md) | [English](https://longbridge.com/en/news/275256031.md)


# InnoCare Pharma erhält IND-Zulassung für klinische Studie mit VAV1-Degrader ICP-538 in China

InnoCare Pharma Ltd. hat bekannt gegeben, dass die chinesische Arzneimittelbehörde National Medical Products Administration (NMPA) die Genehmigung für den Beginn klinischer Studien mit ICP-538 erteilt hat. ICP-538 ist ein VAV1-gerichteter molekularer Glue Degrader zur Behandlung von Autoimmunerkrankungen. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9650953-en) on February 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md)
- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md)
- [InnoCare Pharma (688428.CN)](https://longbridge.com/zh-HK/quote/688428.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md)
- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md)

## 相關資訊與研究

- [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/zh-HK/news/281662341.md)
- [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/zh-HK/news/280923090.md)
- [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/zh-HK/news/281458440.md)
- [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/zh-HK/news/281501537.md)
- [SSY Group Wins China Approval for Upadacitinib Bulk Drug](https://longbridge.com/zh-HK/news/281103720.md)